2025-12-13 - Analysis Report
Okay, here's a comprehensive report and analysis of Johnson & Johnson (JNJ) based on the data provided, aiming for clarity and actionable insights.

**1) Return Rate Comparison vs. S&P 500 (VOO)**

*   **Company Overview:** Johnson & Johnson is a global healthcare company that develops and manufactures pharmaceuticals, medical devices, and consumer packaged goods.
*   **JNJ Cumulative Return:** 59.78%
*   **VOO Cumulative Return:** 102.37%
*   **Divergence:** -42.3 (Current)
*   **Relative Divergence:** 28.3

**Analysis:** JNJ has significantly underperformed the S&P 500 over the specified period, with a divergence of -42.3%. A relative divergence of 28.3 indicates that the current divergence is closer to the minimum end of its historical range. This suggests the stock is currently underperforming, but the degree of underperformance is not unprecedented.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha   | Beta   | Cap(B)  |
|------------|--------|--------|---------|--------|---------|
| 2015-2017  | 26.0%  | 66.8%  | -2.0%   | -0.1   | 344.8   |
| 2016-2018  | 14.0%  | 10.7%  | -1.0%   | 0.1    | 318.5   |
| 2017-2019  | 20.0%  | 71.5%  | -2.0%   | 0.4    | 360.0   |
| 2018-2020  | 19.0%  | 79.2%  | -4.0%   | 0.4    | 388.4   |
| 2019-2021  | 33.0%  | 79.2%  | -14.0%  | 0.5    | 422.2   |
| 2020-2022  | 8.0%   | 79.6%  | 9.0%    | 0.4    | 436.0   |
| 2021-2023  | -19.0% | 79.6%  | -20.0%  | 0.3    | 386.9   |
| 2022-2024  | -32.0% | 79.6%  | -53.0%  | 0.3    | 356.9   |
| 2023-2025  | 31.0%  | 79.6%  | -36.0%  | 0.1    | 509.8   |

**Analysis:**

*   **Alpha:**  JNJ has consistently displayed negative alpha values in most periods, indicating underperformance relative to its benchmark (S&P 500).  The 2020-2022 period is a notable exception.
*   **Beta:**  The beta values are generally low (close to 0), suggesting that JNJ's price is not highly correlated with the market. This indicates that the stock may be less sensitive to overall market movements.
*   **CAGR & MDD:**  The CAGR (Compound Annual Growth Rate) fluctuates significantly, and MDD (Maximum Drawdown) is quite high, suggesting substantial volatility and risk.
*   **Cap(B):** Market capitalization has generally increased over time, except for recent periods where it declined.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 206.54
*    **Last-market**: price': 211.58, 'previousClose': 210.01, 'change': 0.75
*   **5-day SMA:** 202.51
*   **20-day SMA:** 202.52
*   **60-day SMA:** 191.92

**Analysis:** The current price is above all three moving averages, which could suggest an upward trend.  However, the 5-day and 20-day SMAs are very close, indicating recent price consolidation. The large increase relative to the previous day's closing price of 0.75 may reflect short-term price volatility.

**3) Technical Indicators**

*   **MRI:** 0.8 (Medium Investment Recommended)
*   **RSI:** 60.39
*   **PPO:** -0.33
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (5 shares - Very Safe - MRI:0.90)
*   **Recent (20 days) relative divergence change:** -3.1 (Negative, Short-term decline)
*   **Expected Return (%):** -56.6%

**Analysis:**

*   **MRI:** A reading of 0.8 suggests a medium level of investment risk, indicating moderate investment is recommended.
*   **RSI:** An RSI of 60.39 is approaching overbought territory (above 70) but is not there yet, suggesting upward momentum but not extreme conditions.
*   **PPO:** A negative PPO (-0.33) indicates that the shorter-term moving average is below the longer-term moving average, which can be a bearish signal.
*   **Hybrid Signal:** The signal recommends buying 100% of available cash, portraying it as a very safe investment with an MRI of 0.90.
*   **Divergence Change:** The recent decline in relative divergence indicates that JNJ's underperformance compared to the S&P 500 has worsened in the short term.
*   **Expected Return:** The very negative expected return (-56.6%) is a major concern.

**4) Recent News & Significant Events**

*   **Key Themes:** Analyst targets, cash flow justification, institutional investor activity, pipeline breakthroughs, and talc risks.

**Analysis:**  The news headlines present a mixed picture:

*   **Positive:** Articles highlight potential pipeline breakthroughs and discuss institutional investors increasing their stakes, suggesting confidence from some quarters.
*   **Neutral/Questioning:** Articles analyzing cash flow and earnings outlook aim to determine if the recent stock surge is justified.
*   **Negative:** Mentions of talc risks indicate ongoing legal uncertainties.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (Mean 2.16 on a 1-5 scale)
*   **Target Price (avg/high/low):** 206.34 / 240.00 / 155.00
*   **Recent Rating Changes:** Not Available

**Analysis:** While the analyst consensus is generally positive ("Buy"), the average target price (206.34) is around the current price of 206.54, suggesting limited immediate upside potential based on analyst estimates. The wide range between high and low target prices (155.00 to 240.00) indicates uncertainty in the outlook.

**5) Recent Earnings Analysis**

| 날짜       | EPS   | 매출       |
|------------|-------|------------|
| 2025-10-22 | 2.14  | 23.99 B$   |
| 2025-07-24 | 2.3   | 23.74 B$   |
| 2025-04-23 | 4.57  | 21.89 B$   |
| 2024-10-23 | 1.12  | 22.47 B$   |
| 2025-10-22 | 1.12  | 22.47 B$   |

**Analysis:**
*   Revenue has generally been increasing over the last few quarters.
*   EPS has fluctuated considerably. The EPS on 2025-04-23 (4.57) is significantly higher than the other reported quarters.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-09-30 | $23.99B   | 69.56%        |
| 2025-06-30 | $23.74B   | 67.87%        |
| 2025-03-31 | $21.89B   | 66.40%        |
| 2024-12-31 | $22.52B   | 68.35%        |
| 2024-09-30 | $22.47B   | 69.01%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE   |
|------------|-----------|-------|
| 2025-09-30 | $79.28B   | 6.50% |
| 2025-06-30 | $78.47B   | 7.06% |
| 2025-03-31 | $78.11B   | 14.08% |
| 2024-12-31 | $71.49B   | 4.80% |
| 2024-09-30 | $70.16B   | 3.84% |

**Analysis:**

*   **Revenue & Profit Margin:** Both revenue and profit margins show a healthy and relatively consistent trend over the last five quarters.
*   **Equity & ROE:** Equity has been increasing, which is positive. ROE (Return on Equity) fluctuated with a very high number on 2025-03-31, but overall, profitability seems to be improving.

**7) Comprehensive Analysis (Summary)**

*   **Underperformance:** JNJ has significantly underperformed the S&P 500, and recent data indicates this trend may be continuing.
*   **Mixed Signals:** Technical indicators offer conflicting signals, with RSI suggesting potential upside but PPO indicating bearish momentum. Analyst consensus is a "Buy," but target prices suggest limited immediate gains.
*   **Financial Health:** Revenue and profit margins are strong, and equity is growing. However, ROE fluctuations need to be investigated.
*   **Risks:** The extremely negative expected return (-56.6%) is a serious red flag. Ongoing legal challenges (talc) also present a risk.
*   **Recommendation:** Given the underperformance, mixed technicals, and significantly negative expected return, caution is warranted. While analysts remain positive, a deeper investigation is needed to understand the reasons behind the extremely low expected return and to assess the impact of potential liabilities on the company's future prospects. Investors should weigh the potential rewards against the considerable risks before making any investment decisions.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.